Edition:
United Kingdom

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.49EUR
20 Feb 2018
Change (% chg)

€-0.00 (-0.06%)
Prev Close
€8.49
Open
€8.56
Day's High
€8.56
Day's Low
€8.38
Volume
23,844
Avg. Vol
98,514
52-wk High
€18.07
52-wk Low
€7.53

Chart for

About

AB Science SA, also known as AB Science, is a France-based pharmaceutical company specialized in the research, discovery, development and marketing of protein kinase inhibitors (PKIs). It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer,... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €367.11
Shares Outstanding(Mil.): 40.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size

* REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE

04 Jan 2018

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

21 Nov 2017

BRIEF-AB science announces ‍preclinical data showing protective effect of masitinib

* ‍PRECLINICAL DATA SHOWING PROTECTIVE EFFECT OF MASITINIB ON PERIPHERAL NERVOUS SYSTEM IN ALS PUBLISHED IN JOURNAL OF CLINICAL INVESTIGATION INSIGHT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Oct 2017

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

14 Sep 2017

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

31 Aug 2017

Earnings vs. Estimates